Read More

C4 Therapeutics Presents New Preclinical Data For CFT1946 Highlighting Superior Activity As A Single Agent To Clinically Approved BRAF Inhibitor Standard Of Care Combinations At The American Association For Cancer Research Annual Meeting 2024

C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, presented a poster today at the American Association for Cancer Research

CCCC

Read More

C4 Therapeutics Announces 2024 Priorities; Unaudited Cash, Cash Equivalents and Marketable Securities Totaling ~$330M As of January 5, 2024 To Advance Portfolio Of Targeted Protein Degradation Medicines; Announces Workforce Reduction Of ~30%

Multiple 2024 Clinical Updates Expected, Including Data from the Ongoing CFT7455 and CFT1946 Phase 1 Dose Escalation Trials Prioritization of CFT7455, CFT1946, Discovery Collaborations and Focused Discovery Research

CCCC

Read More

Why Despegar.com Shares Are Trading Higher By Over 16%? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session

Shares of Despegar.com, Corp. (NYSE: DESP) rose sharply during Wednesday’s session after the company raised its FY23 financial guidance. The company said it now sees revenue of $690 million to $700 million, versus previous forecast of $670 million to $700 million.

ABM